The World Desk · slice 04
Health & Bio Desk
Regulatory decisions, clinical trials, and the oncology literature. This desk keeps the health slice of our record, from FDA actions to published research. Each finding shows how many separate publishers carried it.
$1.6T: annual sales of the global pharmaceutical market — industry estimates.
What this desk is
Regulatory decisions, clinical-trial readouts, drug and diagnostic approvals, and the oncology research frontier.
Not on this desk: Drug-enforcement and narcotics policing, dropped by name, and consumer wellness coverage that carries no clinical or regulatory finding.
- What is on the page now: 29 items from 21 sources, the earliest dated 2026-09-30. Drawn from 888 fresh items across 364 sources on this beat.
- How often it changes: rebuilt every snapshot; as of 2026-11-10.
- Daily brief: none yet. This desk has no daily brief; the page itself is the desk, rebuilt every snapshot.
- How a tier is earned: A tier is earned by independent origins, not by volume: each newsroom that reported an event on its own counts once, and every syndicated copy of a single wire counts once in total.
Contracts & awards
Award and solicitation records from SAM.gov and USAspending.
- MOTOROLA SOLUTIONS, INC. — $39K — Drug Enforcement Administration: Department of Justice
- COMCAST CABLE COMMUNICATIONS, LLC — $25K — Drug Enforcement Administration: Department of Justice
- LENCO INDUSTRIES, INC. — $2.2M — Drug Enforcement Administration: Department of Justice
- Courier Services at Brian D. Allgood Army Community Hospital for the Department of Pathology and Pharmacy: DEFENSE HEALTH AGENCY HCD WEST · Award Notice
- Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance: NATIONAL INSTITUTES OF HEALTH OLAO · Presolicitation · closes 2026-11-09
On the desk wire
Names native to this desk moving across our whole record right now. Open one for momentum, coverage, and the read.
Our read
What more than one publisher carried on this desk between 2026-11-04 and 2026-11-10, as of 2026-11-10. The count is publishers: a wire story picked up by fifteen outlets counts once.
Carried by more than one publisher Measured
No event on this desk had more than one publisher in the window.
Changed since the last snapshot Measured
- Nothing entered or left this desk’s corroborated list since the last snapshot.
Not yet read on this desk: single-publisher events; contradictions. Not yet read is not the same as none.
This counts how many separate publishers carried an event. It does not show whether the event is true. Many outlets repeating one official statement still rest on one source. The whole week’s corroborated record.
In the coverage
What this desk’s sources reported most recently, newest first: the links behind the read above. Distilled from 888 fresh items across 364 sources on this desk’s beat; the full record feeds every desk, and these are the top reads.
- [APPROVAL] FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
- [APPROVAL] FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
- [APPROVAL] FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer
- [APPROVAL] FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
- Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials
- Psychedelic pioneer Compass files for FDA approval as rivals close in
- Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial
- FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer
- STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke
- FDA clears Onkos Surgical’s NanoCept technology
- 2MM: Pharma Roundup – First DNA therapy approved which could reduce airway surgeries, novel siRNA targets dual lipid pathways, GLP-1s outperform metformin in prediabetes,
- LifeBiotic launches Phase II trial of botanical bladder cancer treatment
- FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma
- Vir says hepatitis D drug combination succeeds in first pivotal study
- FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
- FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia
- TAVO412, an Anti-EGFR, cMET and VEGF Trispecific Antibody: Initial Results from a Phase I Dose Escalation Study in Patients with Advanced Solid Tumors.
- Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial
- Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial.
- Phase III data support a novel trifluridine–tipiracil dosing schedule
- Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial
- The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study.
- A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with
- USFDA Oncology Drug Approvals from 2014- 2025: Comparing non-immunotherapy and immunotherapy approvals, their endpoints, and their efficacy.
Ask the record
No subject on this desk was carried by more than one publisher in the current window, so there is no question to suggest. Ask a question of the record about any subject.
Follow the Health & Bio Desk
This desk has no daily brief yet. The page is rebuilt with every snapshot and shows what more than one publisher carried and what changed since the last one. Leave your address and we will write once, when the Health & Bio Desk brief starts. Nothing else is sent.
Informational only, not investment advice. Market-size figures are editorial estimates with sources as noted; contract and award lines are drawn from public federal records via our tracked pipelines.